Zensun Raises $76 Million for Novel Drug Portfolio

Zensun ( Shanghai ) Science & Technology raised $76 million from a group of investors led by SDIC Venture Capital Management, which contributed half of the funding itself. Zensun's lead drug is Neucardin™, a novel treatment for chronic heart failure that is aimed at building the heart muscle. Zensun believes the drug, which has completed several Phase II trials in China and the US , will prove to improve cardiac function rather than treating the symptoms of cardiac disease. More details.... Share this with colleagues: // //